Substance
DENOSUMAB
Global reference: every product and company linked to this substance.
- cas: 615258-40-7
- ncit: C61313
- rxnorm: 993449
- unii: 4EQZ6YO2HI
AMG-162 · AMG162 · denosumab [INN] · DENOSUMAB [JAN] · DENOSUMAB [USAN] · Denosumab [WHO-DD] · PROLIA · XGEVA
Revenue by product (3)
| Company | Product | Latest period | Revenue |
|---|---|---|---|
| AMGEN INC. COMMON STOCK | PROLIA | Q2 2026 | $759.0M |
| AMGEN INC. COMMON STOCK | XGEVA | Q2 2026 | $352.0M |
| AMGEN INC. COMMON STOCK | XGEVA | Q2 2026 | $352.0M |
A figure belongs to the product it was reported for. It is never summed across companies or across a company's products, so one substance in three products shows three figures.
Products containing this substance (3)
- PROLIA · AMGEN INC. COMMON STOCK
- XGEVA · AMGEN INC. COMMON STOCK
- XGEVA · AMGEN INC. COMMON STOCK